Combination treatment with immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) demonstrated overall survival benefit for patients with melanoma that has spread to the brain, according to phase II study results published in The Lancet Oncology by researchers at MD Anderson Cancer Center.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe